Vicore Pharma Holding AB (publ) announced that the board of directors has resolved to appoint Ahmed Mousa as new CEO of the company with start in September 2023. This follows the July 5 announcement that Carl-Johan Dalsgaard plans to retire as CEO of the company. Ahmed Mousa is an experienced biotechnology executive with deep expertise in business and corporate development across several therapeutic areas, including respiratory disease.

He joins the company from Pieris Pharmaceuticals where he served as Chief Business Officer. During his time at Pieris, Ahmed executed strategic partnerships yielding over USD 400 million in upfront, milestone, and co-development program investment, and over USD 6 billion in milestone potential with leading biopharmaceutical companies including AstraZeneca, Genentech, Seagen and Servier. He also played a leading role in growing Pieris from less than 30 employees in 2016 to approximately 150 in 2022 and in the advancement of multiple therapeutic programs from concept to clinical studies.

Ahmed is a US citizen and resides in Boston, Massachusetts. Prior to joining Pieris, Ahmed was an attorney with the law firm Covington & Burling, where he represented pharmaceutical and biotech companies in a range of matters. He was previously a law clerk at the US Court of Appeals for the Third Circuit and an IP associate at the law firm Kirkland & Ellis.

Ahmed obtained undergraduate degrees in molecular biology and government from Cornell University and a Master's degree in biotechnology from John Hopkins University with research experience focused in oncology, angiogenesis, and--notably--angiotensin II biology. He obtained a Juris Doctor degree from Georgetown Law with honors, where he was the Editor-in-Chief of the Georgetown Journal of International Law.